Company news
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) news
Olema Pharmaceuticals, Inc. news releases on 6ix. Latest, Mar 11, 2024: Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results…
Press releases — page 2
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 10, 2024
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
March 5, 2024
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 7, 2024
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 4, 2023
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 27, 2023
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 6, 2023
Olema Oncology to Participate in Upcoming Investor Conferences in November
October 31, 2023
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 21, 2023
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 16, 2023
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 15, 2023
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
October 11, 2023
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
October 9, 2023
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
Olema Oncology Announces Combined Financing for Up to $180 Million
September 4, 2023
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 7, 2023
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
July 31, 2023
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
May 29, 2023
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
May 10, 2023
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
May 7, 2023
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
April 12, 2023
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
March 8, 2023
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
March 1, 2023
Olema Oncology to Participate at Upcoming Investor Conferences
February 20, 2023
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
December 6, 2022
Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
November 20, 2022
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Olema Oncology to Present at Upcoming Investor Conferences in November
October 31, 2022
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
October 25, 2022
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 11, 2022
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 8, 2022
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
August 8, 2022
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
August 3, 2022
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
July 20, 2022
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
June 8, 2022
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
June 8, 2022
Olema Oncology to Present at Jefferies Healthcare Conference
May 23, 2022
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 8, 2022
Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2022
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
April 3, 2022
Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 7, 2022
Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 27, 2022
Olema Oncology to Present at Cowen 42nd Annual Health Care Conference
February 21, 2022
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
January 30, 2022
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
November 29, 2021
Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
November 28, 2021